Literature DB >> 21955614

Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.

Tissa T Manavalan1, Yun Teng, Savitri N Appana, Susmita Datta, Theodore S Kalbfleisch, Yong Li, Carolyn M Klinge.   

Abstract

Microarrays identified miRNAs differentially expressed and 4-hydroxytamoxifen (4-OHT) regulated in MCF-7 endocrine-sensitive versus resistant LY2 human breast cancer cells. 97 miRNAs were differentially expressed in MCF-7 versus LY2 cells. Opposite expression of miRs-10a, 21, 22, 29a, 93, 125b, 181, 200a, 200b, 200c, 205, and 222 was confirmed. Bioinformatic analyses to impute the biological significance of these miRNAs identified 36 predicted gene targets from those regulated by 4-OHT in MCF-7 cells. Agreement in the direction of anticipated regulation was detected for 12 putative targets. These miRNAs with opposite expression between the two cell lines may be involved in endocrine resistance.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21955614      PMCID: PMC3214732          DOI: 10.1016/j.canlet.2011.08.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  83 in total

Review 1.  Mechanisms of tamoxifen resistance.

Authors:  Alistair Ring; Mitch Dowsett
Journal:  Endocr Relat Cancer       Date:  2004-12       Impact factor: 5.678

2.  Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.

Authors:  Gary K Scott; Andrei Goga; Dipa Bhaumik; Crystal E Berger; Christopher S Sullivan; Christopher C Benz
Journal:  J Biol Chem       Date:  2006-11-16       Impact factor: 5.157

3.  Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells.

Authors:  M F El Etreby; Y Liang; R W Wrenn; P V Schoenlein
Journal:  Breast Cancer Res Treat       Date:  1998-09       Impact factor: 4.872

4.  Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products.

Authors:  N E Davidson; D A Bronzert; P Chambon; E P Gelmann; M E Lippman
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

5.  miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer.

Authors:  S Uhlmann; J D Zhang; A Schwäger; H Mannsperger; Y Riazalhosseini; S Burmester; A Ward; U Korf; S Wiemann; O Sahin
Journal:  Oncogene       Date:  2010-05-31       Impact factor: 9.867

6.  Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.

Authors:  Jonna Frasor; Edmund C Chang; Barry Komm; Chin-Yo Lin; Vinsensius B Vega; Edison T Liu; Lance D Miller; Johanna Smeds; Jonas Bergh; Benita S Katzenellenbogen
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

Review 7.  Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis.

Authors:  Konstantinos P Economopoulos; Theodoros N Sergentanis
Journal:  Breast Cancer Res Treat       Date:  2010-01-07       Impact factor: 4.872

Review 8.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

Authors:  Robert Clarke; Minetta C Liu; Kerrie B Bouker; Zhiping Gu; Richard Y Lee; Yuelin Zhu; Todd C Skaar; Bianca Gomez; Kerry O'Brien; Yue Wang; Leena A Hilakivi-Clarke
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

9.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.

Authors:  Heidi J Peltier; Gary J Latham
Journal:  RNA       Date:  2008-03-28       Impact factor: 4.942

10.  Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.

Authors:  Anatasha C Crawford; Rebecca B Riggins; Ayesha N Shajahan; Alan Zwart; Robert Clarke
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240

View more
  37 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.

Authors:  Kideok Jin; Sunju Park; Wei Wen Teo; Preethi Korangath; Sean Soonweng Cho; Takahiro Yoshida; Balázs Győrffy; Chirayu Pankaj Goswami; Harikrishna Nakshatri; Leigh-Ann Cruz; Weiqiang Zhou; Hongkai Ji; Ying Su; Muhammad Ekram; Zhengsheng Wu; Tao Zhu; Kornelia Polyak; Saraswati Sukumar
Journal:  Cancer Discov       Date:  2015-07-15       Impact factor: 39.397

3.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

Review 4.  The novel role of miRNAs for tamoxifen resistance in human breast cancer.

Authors:  Wenwen Zhang; Jing Xu; Yaqin Shi; Qian Sun; Qun Zhang; Xiaoxiang Guan
Journal:  Cell Mol Life Sci       Date:  2015-03-18       Impact factor: 9.261

5.  Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.

Authors:  Penn Muluhngwi; Abirami Krishna; Stephany L Vittitow; Joshua T Napier; Kirsten M Richardson; Mackenzie Ellis; Justin L Mott; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

6.  Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells.

Authors:  Yun Teng; Tissa T Manavalan; Chuan Hu; Svjetlana Medjakovic; Alois Jungbauer; Carolyn M Klinge
Journal:  Toxicol Sci       Date:  2012-10-10       Impact factor: 4.849

7.  Antiestrogen Resistance and the Application of Systems Biology.

Authors:  Kerrie B Bouker; Yue Wang; Jianhua Xuan; Robert Clarke
Journal:  Drug Discov Today Dis Mech       Date:  2012-12-01

Review 8.  miR-221/222: promising biomarkers for breast cancer.

Authors:  Wei-Xian Chen; Qing Hu; Man-Tang Qiu; Shan-Liang Zhong; Jin-Jin Xu; Jin-Hai Tang; Jian-Hua Zhao
Journal:  Tumour Biol       Date:  2013-03-27

9.  Identification of microRNA-regulated autophagic pathways in plant lectin-induced cancer cell death.

Authors:  L-L Fu; X Zhao; H-L Xu; X Wen; S-Y Wang; B Liu; J-K Bao; Y-Q Wei
Journal:  Cell Prolif       Date:  2012-08-08       Impact factor: 6.831

Review 10.  miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.

Authors:  Merve Mutlu; Umar Raza; Özge Saatci; Erol Eyüpoğlu; Emre Yurdusev; Özgür Şahin
Journal:  J Mol Med (Berl)       Date:  2016-04-20       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.